Spur Therapeutics
Toward the next generation of gene therapy.
Toward the next generation of gene therapy.
Freeline is a biopharmaceutical company focused on developing liver-directed gene therapies for inherited systemic diseases. With clinical programs for Hemophilia B and Fabry disease, and preclinical programs in Gaucher disease and haemophilia A, the company aims to revolutionize treatment options for individuals suffering from debilitating inherited diseases. Founded in 2015, Freeline is based in the United Kingdom, with additional locations in the United States and Germany. The company recently received a notable $26.10M post-IPO equity investment on 10 March 2022, with Syncona Investment Management as the investors. This significant funding reflects investor confidence in Freeline's innovative approach to gene therapy, positioning the company for further growth and impact in the biopharma, biotechnology, and life sciences industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $26.10M | 1 |
|
10 Mar 2022 |
| Series C | $80.00M | 6 |
|
30 Jun 2020 |
| Series C | $40.00M | 1 |
|
19 Dec 2019 |
| Grant | Unknown | 1 |
|
24 May 2019 |
| Series B | £88.40M | 2 |
|
20 Jun 2018 |
No recent news or press coverage available for Spur Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
